Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CORV - Correvio Pharma Corp.

Previous close
0.4199
0   0%

Share volume: 0
Last Updated: Tue 26 May 2020 06:00:00 AM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$0.42
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 33%
Dept financing 22%
Liquidity 16%
Performance 35%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.42
P/E Ratio 
N/A
DAY RANGE
$0.42 - $0.42
EPS 
-$0.82
52 WEEK RANGE
$0.21 - $2.79
52 WEEK CHANGE
-$81.09
MARKET CAP 
27.800 M
YIELD 
N/A
SHARES OUTSTANDING 
66.191 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$23,236,615
AVERAGE 10 VOLUME 
$559,881
AVERAGE 30 VOLUME 
$1,902,133
Company detail
CEO:
Region: US
Website: http://www.correvio.com
Employees: 133
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Recent news